Jiangsu Vcare PharmaTech Co. Ltd. located in Nanjing Jiangbei New Area, one of state-level new areas is a high-tech company providing research and development services for the whole industry chain of chemical drugs. Vcare specializes in R&D, application and domestic/international transfer of generic and innovative drugs and R&D, manufacture and sales of featured pharmaceutical intermediates.
Vcare was founded by professors of China Pharmaceutical University and overseas returnees in August 2010 and joined Jilin Yatai Group, one of China’s top 500 enterprises in March 2015. Now Vcare has almost up to 160 researchers including 7 doctors and 60 masters. The whole team has many years of industry background and strong technological advantages in chemical synthesis and generic and innovative drug development, and has extensive experience in business management. Vcare has 5,000m2 comprehensive R&D center as well as several cooperative manufacturing bases and is honored as National High-Tech Enterprise, Nanjing Chemical Drug Engineering Technology Research Center, Jiangbei New Area Lingque Enterprise and co-built a provincial graduate workstation with China Pharmaceutical University. Vcare takes the international advanced management mode to operate well-equipped laboratories for synthesis, analysis, formulation, cell and enzyme activity detection and has an experienced clinical audit management team. Vcare can provide clients with "chemical + pharmaceutical + clinical" full-industry chain development services based on well-developed research and development system, quality management system and production conditions. Vcare’s 21,000 m2 new R&D center and headquarter are under construction in Nanjing Biomedicine Valley, Jiangbei New Area and 30,000 m2 GMP factory is under construction in Jiangsu Nantong, both will come into service in 2019.
Vcare has formed innovative drug, generic drug and pharmaceutical intermediate pipelines mainly focusing on cardiac-cerebral vascular, tumor and endocrine areas. There are 23 generic drug projects, 13 quality consistency evaluation projects and 6 clinical projects under researching in R&D center and clinical trial institutions. Up to now, Vcare has applied 1 IND and 12 ANDAs and assisted clients with obtaining 9 clinical trial approvals and 4 production licenses. Vcare’s IND Vicagrel has successively obtained “Twelfth Five-Year Plan” and “Thirteenth Five-Year Plan” national major support. There are 21 featured generics intermediate projects under manufacturing in Vcare’s cooperative bases. Vcare has accumulatively applied 30 domestic and international patents and 11 domestic and 4 foreign patents have been authorized.
Vicagrel is a new antiplatelet drug jointly developed by Jiangsu VcarePharmatech Co., Ltd. and China Pharmaceutical University. The IP right of Vicagrel is wholly owned by Jiangsu Vcare Pharmatech Co., Ltd. The NCE and process patent of Vicagrel has been authorized in China, US, Japan, EU and Canada. Moreover, the related PCT application has entered the national phase in more than 30 countries. A related research paper was published in the Journal of Medicinal Chemistry (2012, 55, 3342–3352) and was highlighted in SciBX under the Nature publishing group.